a:1:{s:5:"entry";a:1:{i:0;a:11:{s:4:"hash";s:64:"4ecf302c4af792db055a30c6216091ba59db0346ae3791635ad68f04f36e26ac";s:11:"requestHash";s:10:"phpbiotech";s:10:"profileUrl";s:31:"https://gravatar.com/phpbiotech";s:17:"preferredUsername";s:10:"phpbiotech";s:12:"thumbnailUrl";s:94:"https://2.gravatar.com/avatar/4ecf302c4af792db055a30c6216091ba59db0346ae3791635ad68f04f36e26ac";s:6:"photos";a:1:{i:0;a:2:{s:5:"value";s:62:"https://2.gravatar.com/avatar/abf14cb527a1307aecd1e3154128eb11";s:4:"type";s:9:"thumbnail";}}s:11:"displayName";s:11:"PHP Biotech";s:7:"aboutMe";s:623:"PHP Biotech is a US-based biotechnology company developing first-in-class nanobody therapeutics for the most aggressive and hard-to-treat cancers. Our lead candidate, PHP53-nb, is a patented, humanized camelid nanobody that enters cancer cells and reactivates mutant p53 to trigger apoptosis—showing strong anti-tumor efficacy and low toxicity in model systems across triple-negative breast cancer (TNBC), ovarian, and other tumors. Backed by a world-class scientific team and global CRO and CDMO partners, we're advancing a versatile platform and pipeline to transform cancer care and improve patient outcomes worldwide.";s:15:"currentLocation";s:44:"550 Reserve St. STE 190, Southlake, TX 76092";s:17:"profileBackground";a:5:{s:5:"color";s:7:"#2b3529";s:7:"opacity";d:1;s:4:"size";i:100;s:13:"primary_color";s:7:"#275e29";s:13:"surface_color";s:7:"#f8fef8";}s:12:"header_image";a:6:{s:4:"fill";s:4:"full";s:4:"size";i:100;s:10:"position_x";i:50;s:10:"position_y";i:50;s:8:"image_id";s:32:"c65c77cbf47869c2309fa9faf37d0b0b";s:18:"hide_default_image";b:0;}}}}